[{"indications": "Indications\u00a0see under Dose (should only be given by specialists)", "name": "PENTAMIDINE ISETIONATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.4 Antiprotozoal drugs", "5.4.8 Drugs for pneumocystis pneumonia"], "cautions": "Cautions\u00a0risk of severe hypotension following\r\nadministration (monitor blood pressure\r\nbefore starting treatment, during administration, and at regular intervals,\r\nuntil treatment concluded; patient should\r\nbe lying down when receiving drug parenterally); hypokalaemia, hypomagnesaemia, coronary heart disease, bradycardia, history of\r\nventricular arrhythmias, concomitant use\r\nwith other drugs which prolong QT-interval; hypertension or hypotension; hyperglycaemia or hypoglycaemia; leucopenia, thrombocytopenia, or anaemia; carry out laboratory\r\nmonitoring according to product literature; care required to protect personnel during handling and administration; interactions: Appendix 1 (pentamidine isetionate)", "side-effects": "Side-effects\u00a0severe reactions, sometimes fatal, due to hypotension,\r\nhypoglycaemia, pancreatitis, and arrhythmias; also leucopenia, thrombocytopenia,\r\nacute renal failure, hypocalcaemia; also reported: azotaemia, abnormal\r\nliver-function tests, anaemia, hyperkalaemia, nausea and vomiting,\r\ndizziness, syncope, flushing, hyperglycaemia, rash, and taste disturbances;\r\nStevens-Johnson syndrome reported; on inhalation, bronchoconstriction\r\n(may be prevented by prior use of bronchodilators), cough, and shortness\r\nof breath; discomfort, pain, induration, abscess formation, and muscle\r\nnecrosis at injection site", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4054.htm", "doses": ["Treatment of Pneumocystis jirovecii (Pneumocystis\r\ncarinii) pneumonia, by intravenous infusion, 4\u00a0mg/kg once daily for at least 14 days", "Prophylaxis of Pneumocystis jirovecii (Pneumocystis\r\ncarinii) pneumonia, by inhalation of nebulised solution (using suitable equipment\u2014consult product literature), 300\u00a0mg every\r\n4 weeks or 150\u00a0mg every 2 weeks [unlicensed for primary\r\nprevention]", "Visceral leishmaniasis (kala-azar, section 5.4.5), by deep intramuscular injection, 3\u20134\u00a0mg/kg on alternate days to max. total of 10 injections; course\r\nmay be repeated if necessary", "Cutaneous leishmaniasis, by deep intramuscular injection, 3\u20134\u00a0mg/kg once or twice weekly until condition resolves (but see\r\nalso section 5.4.5)", "Trypanosomiasis, by deep intramuscular injection or intravenous infusion, 4\u00a0mg/kg\r\ndaily or on alternate days to total of 7\u201310 injections", "Direct intravenous injection should be avoided\r\nwhenever possible and never given rapidly; intramuscular\r\ninjections should be deep and preferably given into the buttock"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid unless essential"}]